Between January and November 2018, Russia imported 475.3 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices, VAT included), which is in monetary terms 0.5% higher than that of the same period of 2017, and 97.3 bln RUB worth of in-bulk drugs, which is 13.6% higher than that of the same period of 2017. The total dynamics in monetary terms are +2.5%.

In physical terms, Russia imported 1.7 bln units of ready-made pharmaceuticals, which is 8.2% lower than that of the same period of 2017, and 3.8 bln minimum dosage units (MDU) of in-bulk pharmaceuticals, which is nearly 3% lower than that of the same period of 2017. In November 2018, Russia imported 264 mln MDUs of in-bulk pharmaceuticals, which is 35% lower than that of November 2018. Between January and November 2017, Russia imported 34.9 bln MDUs of pharmaceutical drugs (dynamics of -6.1%.)

Among the top 30 trademarks of ready-made pharmaceuticals with the biggest import volume over the period in monetary terms, anti-HIV drug Tivicay by Viiv Healthcare has the highest dynamics (18 times increase.) Nurofen by Reckitt has the worst dynamics (-23%), which is due to a lower import volume in physical terms.

As for in-bulk drugs, anti-tumor Imbruvica by Johnson & Johnson appeared on the Russian market in January 2018. It is packaged at the facilities of Pharmstandard-UfaVITA. Faslodex by AstraZeneca has the worst dynamics (-34%.)

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – November 2018)